A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4358-4366

  Bleeker, Nicholas P ^a   Cornea, Razvan L ^a   Thomas, David D ^a   Xing, Chengguo ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cancer; drug resistance; inhibitor; SERCA; synergy

Indexed keywords

2,5 DI TERT BUTYLHYDROQUINONE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; CALCIUM; CXL 017; CYCLOPIAZONIC ACID; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; THAPSIGARGIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG POTENTIATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL;

BENZOPYRANS; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84887388584     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400458u     Document Type: Article

References (43)

1. Fojo, T.; Bates, S. Strategies for reversing drug resistance Oncogene 2003, 22, 7512-7535
2. Szakács, G.; Paterson, J.; Ludwig, J.; Booth-Genthe, C.; Gottesman, M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery. 2006, 5, 219-253
3. Fesik, S. Promoting apoptosis as a strategy for cancer drug discovery Nat. Rev. Cancer 2005, 5, 876-961
4. Campos, L.; Guyotat, D.; Archimbaud, E.; Calmard-Oriol, P.; Tsuruo, T.; Troncy, J.; Treille, D.; Fiere, D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis Blood 1992, 79, 473-479
5. Del Poeta, G.; Venditti, A.; Del Principe, M.; Maurillo, L.; Buccisano, F.; Tamburini, A.; Cox, M.; Franchi, A.; Bruno, A.; Mazzone, C.; Panetta, P.; Suppo, G.; Masi, M.; Amadori, S. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Blood 2003, 101, 2125-2156
6. Gottesman, M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53, 615-642
7. Rong, Y.; Distelhorst, C. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis Annu. Rev. Physiol. 2008, 70, 73-164
8. 2+ signaling J. Biol. Chem. 2010, 285, 13678-13762
9. 2+-ATPase (SERCA) Biochem. J. 2004, 383, 361-431
10. 2+ transfer in the control of apoptosis Oncogene 2008, 27, 6407-6425
11. Mattson, M.; Chan, S. Calcium orchestrates apoptosis Nat. Cell Biol. 2003, 5, 1041-1044
12. Groenendyk, J.; Michalak, M. Endoplasmic reticulum quality control and apoptosis Acta Biochim. Polon. 2005, 52, 381-476
13. Deniaud, A.; Sharaf el dein, O.; Maillier, E.; Poncet, D.; Kroemer, G.; Lemaire, C.; Brenner, C. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis Oncogene 2008, 27, 285-384
14. Sulová, Z.; Seres, M.; Barancík, M.; Gibalová, L.; Uhrík, B.; Poleková, L.; Breier, A. Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis Gen. Phys. Biophys. 2009, 28, 89-95
15. Berridge, M.; Bootman, M.; Roderick, H. Calcium signalling: dynamics, homeostasis and remodelling Nat. Rev. Mol. Cell Biol. 2003, 4, 517-546
16. Periasamy, M.; Kalyanasundaram, A. SERCA pump isoforms: their role in calcium transport and disease Muscle Nerve 2007, 35, 430-472
17. Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: the calcium-apoptosis link Nat. Rev. Mol. Cell Biol. 2003, 4, 552-617
18. 2+ pump inhibitors Biochem. Soc. Trans. 2011, 39, 789-886
19. 2+-ATPases Trends Pharmacol. Sci. 1998, 19, 131-136
20. 2+-pump inhibitors thapsigargin and cyclopiazonic acid induce stress proteins in mammalian chondrocytes Biochem. J. 1994, 301, 563-571
21. 2+ pool J. Biol. Chem. 1989, 264, 15192-15200
22. Olesen, C.; Picard, M.; Winther, A.-M. L.; Gyrup, C.; Morth, J.; Oxvig, C.; Møller, J.; Nissen, P. The structural basis of calcium transport by the calcium pump Nature 2007, 450, 1036-1078
23. Takahashi, M.; Kondou, Y.; Toyoshima, C. Interdomain communication in calcium pump as revealed in the crystal structures with transmembrane inhibitors Proc. Natl. Acad. Sci. 2007, 104, 5800-5805
24. 2+-ATPase with thapsigargin and thapsigargin analogs J. Biol. Chem. 2010, 285, 28883-28975
25. 2+-ATPase of sarcoplasmic reticulum J. Biol. Chem. 1989, 264, 17816-17839
26. 2+-ATPase: separate binding sites for dihydroxybenzenes and sesquiterpene lactones Biochemistry 1995, 34, 14385-14478
27. 2+-ATPase of sarcoplasmic reticulum from paired inhibitor studies Biochemistry 2002, 41, 2869-2944
28. Ghantous, A.; Gali-Muhtasib, H.; Vuorela, H.; Saliba, N. A.; Darwiche, N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discovery Today 2010, 15, 668-678
29. Roti, G.; Carlton, A.; Ross, K. N.; Markstein, M.; Pajcini, K.; Su, A. H.; Perrimon, N.; Pear, W. S.; Kung, A. L.; Blacklow, S. C.; Aster, J. C.; Stegmaier, K. Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer Cancer Cell 2013, 23, 390-405
30. Hermanson, D.; Addo, S.; Bajer, A.; Marchant, J.; Das, S.; Srinivasan, B.; Al-Mousa, F.; Michelangeli, F.; Thomas, D.; Lebien, T.; Xing, C. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria Mol. Pharmacol. 2009, 76, 667-745
31. Das, S.; Srinivasan, B.; Hermanson, D.; Bleeker, N.; Doshi, J.; Tang, R.; Beck, W.; Xing, C. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4 H -chromene-3-carboxylate (CXL017) and its analogues J. Med. Chem. 2011, 54, 5937-5985
32. Aridoss, G.; Zhou, B.; Hermanson, D. L.; Bleeker, N. P.; Xing, C. Structure-Activity Relationship (SAR) Study of Ethyl 2-Amino-6-(3,5- dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4 H -chromene-3-carboxylate (CXL017) and the Potential of the Lead against Multidrug Resistance in Cancer Treatment J. Med. Chem. 2012, 55, 5566-5581
33. Winters, D.; Autry, J.; Svensson, B.; Thomas, D. Interdomain fluorescence resonance energy transfer in SERCA probed by cyan-fluorescent protein fused to the actuator domain Biochemistry 2008, 47, 4246-4302
34. Chou, T.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-82
35. Toyoshima, C.; Nomura, H. Structural changes in the calcium pump accompanying the dissociation of calcium Nature 2002, 418, 605-616
36. 2+ ATPase (SERCA) catalytic cycle Biochemistry 2006, 45, 13769-13847
37. 2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP Eur. J. Biochem. 2001, 268, 6318-6327
38. Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70, 440-446
39. Das, S.; Hermanson, D.; Bleeker, N.; Lowman, X.; Li, Y.; Kelekar, A.; Xing, C. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4 H -chromene-3-carboxylate (CXL017) a novel scaffold that re-sensitizes multidrug resistant leukemia cells to chemotherapy ACS Chem. Biol. 2012, 8, 327-335
40. Chene, P. ATPases as drug targets: learning from their structure Nat. Rev. Drug Discovery 2002, 1, 665-673
41. Mueller, B.; Zhao, M.; Negrashov, I.; Bennett, R.; Thomas, D. SERCA structural dynamics induced by ATP and calcium Biochemistry 2004, 43, 12846-12854
42. Jia, J.; Zhu, F.; Ma, X.; Cao, Z.; Cao, Z.; Li, Y.; Li, Y.; Chen, Y. Mechanisms of drug combinations: interaction and network perspectives Nat. Rev. Drug Discovery 2009, 8, 111-139
43. Chou, T.; Motzer, R.; Tong, Y.; Bosl, G. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J. Natl. Cancer Inst. 1994, 86, 1517-1541